Test Directory
| Test Code | |||||||||||||
| FSIMA | |||||||||||||
| Test Name | |||||||||||||
| IGH::MAF, t(14;16)(q32;q23) by FISH | |||||||||||||
| CPT Codes | |||||||||||||
| 88237, 8837726, 88377TC | |||||||||||||
| Included Tests | |||||||||||||
|
|||||||||||||
| Expected Turnaround Time | |||||||||||||
| 3-5 business days | |||||||||||||
| Clinical Utility | |||||||||||||
|
The t(14;16) is generated during B-cell maturation in germinal centers possibly as a result of errors in the immunoglobulin heavy chain (IGH) switch recombination (Bergsagel et al, 2001). The anomaly appears to be an early event in the genesis of plasma cell neoplasms (PCN) as it occurs in both monoclonal gammopathy of unknown significance (MGUS) and multiple myeloma (MM). The t(14;16)(q32;q23) is detectable in 2–10% of patients with plasma cell myeloma and in about 25% of myeloma cell lines. The t(14;16)(q32;q23) is difficult to detect by conventional karyotypes. The most common additional abnormalities in these series are -13/13q-, amplification of 1q, trisomy or tetrasomy of chromosome 15 and structural (mostly deletions of the short arm in the region 8p21.3) and numerical of chromosome 8. Although some studies report a low prevalence of the t(14;16) in newly diagnosed patients, other studies reveal that a small percentage of patients show the t(14;16) at the time of initial diagnosis. Translocation (14;16)(q32;q23) has also been described in MGUS. The cases with t(14;16) are resistant to bortezomib therapy. FISH can detect this rearrangement in either interphase or metaphase cells. |
|||||||||||||
| Specimen and Container Info | |||||||||||||
|
|||||||||||||
| Collection Instructions | |||||||||||||
|
|||||||||||||
| Processing and Submission Instructions | |||||||||||||
|
Each specimen must be accompanied by a requisition form, script, electronic order or physician note. Each order must indicate the reason for testing (diagnosis). |
|||||||||||||
| Transport Instructions | |||||||||||||
|
|||||||||||||
| Stability Requirements | |||||||||||||
|
|||||||||||||
| Causes for Rejection | |||||||||||||
|
|||||||||||||
| Methodology | |||||||||||||
| FISH, Fluorescence In-Situ Hybridization | |||||||||||||
| Reference Intervals | |||||||||||||
|
In a normal cell, the expected signal pattern is two orange signals and two green signals. In an abnormal cell containing a typical translocation, the expected signal pattern is one orange signal, one green signal, and two fused signals. |
|||||||||||||
| Performing Location | |||||||||||||
| Roble Road Core Laboratory | |||||||||||||
| Alternate Names | |||||||||||||
|
|||||||||||||
| Testing Schedule | |||||||||||||
| Routine, Monday - Friday no holidays | |||||||||||||
| Disease Group | |||||||||||||
| Cytogenetic Tests | |||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.